home / stock / avir / avir news

AVIR News and Press, Atea Pharmaceuticals Inc. From 03/27/24

Stock Information
Company Name: Atea Pharmaceuticals Inc.
Stock Symbol: AVIR
Market: NASDAQ
Website: ateapharma.com
Menu
AVIR AVIR Quote AVIR Short AVIR News AVIR Articles AVIR Message Board
Get AVIR Alerts

News, Short Squeeze, Breakout and More Instantly...
AVIR - Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the...
AVIR - Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Mon...

AVIR - Expected US Company Earnings on Wednesday, February 28th, 2024

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

AVIR - Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...
AVIR - KNDI, IREN and om are among after hour movers

2024-01-10 16:52:44 ET Gainers: MannKind Corporation ( NASDAQ: MNKD ) +5% . Kandi Technologies Group ( KNDI ) +5% . Outset Medical ( OM ) +4% . HWH International ( HWH ) +3% . Atea Pharmaceuticals ( AVIR ) +3% . Losers:...

AVIR - Atea gains after mid-stage data for lead asset in Hepatitis C

2024-01-09 12:50:43 ET More on Atea Pharmaceuticals Atea Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Atea Pharmaceuticals Histor...

AVIR - COMM, NKTX and AVIR are among after hour movers

2024-01-08 16:53:20 ET Gainers: Universe Pharmaceuticals  ( UPC ) +13% . MaxCyte ( MXCT ) +12% . WISeKey International Holding  ( WKEY ) +8% . Alset Capital Acquisition  ( ACAX ) +7% . Atea Pharmaceuticals ( AVIR ) +...
AVIR - Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monotherapy Arm; First Interim Analysis by the Independent Data Safety Monitoring Boar...

AVIR - Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, P...

AVIR - GMAB, FNC and LOVE are among after hour movers

2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares  ( HBANL ) +3% . Genmab  ( GMAB ) +3% . Losers: Fluence En...
Previous 10 Next 10